Provexis PLC Re-appointment to the Scientific Advisory Board (3368Y)
December 01 2014 - 2:00AM
UK Regulatory
TIDMPXS
RNS Number : 3368Y
Provexis PLC
01 December 2014
1 December 2014
Provexis plc
Re-appointment of Professor Asim Duttaroy to the Scientific
Advisory Board
Provexis plc ('Provexis' or the 'Company'), the business that
develops and licenses the proprietary, scientifically-proven
Fruitflow(R) heart-health functional food ingredient, is pleased to
announce the re-appointment of Professor Asim Duttaroy to the
Company's Scientific Advisory Board.
Professor Duttaroy was the original inventor of Fruitflow(R) and
he previously served on the Company's Scientific Advisory Board
from 2003 to 2011.
Professor Duttaroy is a globally recognised expert in the field
of nutrition studies; he is currently Group Leader of Chronic
Disease at the University of Oslo's Faculty of Medicine, and on 5
November 2014 he was appointed as editor in chief of the
international peer reviewed journal Food & Nutrition
Research.
The Company's Scientific Advisory Board (SAB) is now composed of
Professor Asim Duttaroy, the inventor of Fruitflow(R), and Dr Niamh
O'Kennedy, a research chemist specialising in the field of natural
products chemistry. Dr O'Kennedy played a key role in the
development of Fruitflow(R) and the health claim for Fruitflow(R)
which was adopted by the European Food Safety Authority ('EFSA').
The Company's agreements with SAB members include certain
confidentiality, non-compete, IP assignment and first right of view
provisions.
On 18 November 2014 the Company announced it had signed a
collaboration agreement with the University of Oslo to undertake
further research into the relationship between Fruitflow(R) and
blood pressure regulation, with collaboration work to be led by
Professor Duttaroy and Dr O'Kennedy. The company is ideally
positioned to develop technologies designed to extend the existing
'healthy blood flow' product claims of Fruitflow(R), on a carefully
managed and costed basis, with the collaboration expected to be an
important step in maximising the opportunities available to
commercialise the product.
The Company also announced on 18 November 2014 that Professor
Duttaroy and Dr O'Kennedy had been granted certain new options over
Ordinary Shares under the Provexis 2005 share option scheme, which
the Company believes will closely align their interests with those
of shareholders.
Dawson Buck, Chairman of Provexis, commented:
"We are delighted that Professor Duttaroy has re-joined the
Scientific Advisory Board, further strengthening his longstanding
relationship with the Company and its key heart-health functional
food ingredient, Fruitflow.
We believe that Professor Duttaroy will play an important role
in maximising the opportunities available to commercialise
Fruitflow, to the benefit of shareholder value."
- ends -
For further information please contact:
Provexis plc Tel: 07917 670260
Dawson Buck, Chairman enquiries@provexis.com
Ian Ford, Finance Director
Cenkos Securities plc Tel: 020 7397 8900
Bobbie Hilliam
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAAFPALPLFFF
Provexis (LSE:PXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provexis (LSE:PXS)
Historical Stock Chart
From Apr 2023 to Apr 2024